Investment
Features
FeesSafety
Academy
More
Pluang+

Compare IQVIA Holdings Inc. Common Stock (IQV) vs Vir Biotechnology Inc. Common Stock (VIR) Price & Performance

IQVIA Holdings Inc. Common StockTrade
Vir Biotechnology Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

IQVIA Holdings Inc. Common Stock vs Vir Biotechnology Inc. Common Stock — how do they compare? IQVIA Holdings Inc. Common Stock trades at $265 (market cap $42.91B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.76B). The key difference: IQVIA Holdings Inc. Common Stock is far larger — about 24.4× Vir Biotechnology Inc. Common Stock's market cap, and IQVIA Holdings Inc. Common Stock is trading nearer its 52-week high, Vir Biotechnology Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IQVIA Holdings Inc. Common Stock for 6 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.

IQVVIR
Market Cap
$42.91B$1.76B
Volume
1,333,4562,764,948
Sector
HealthHealth
52-Week High
$275.02$11.78
52-Week Low
$156.66$5.12
Typical Hold Time
6 Days0 Days
Enterprise Value
$57.07B$1.32B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

IQVIA Holdings Inc. Common Stock

IQVIA Holdings (IQV) trades at $260.71, down 0.57% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $284.64. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $3.15 surpassing the $3.03 estimate. Revenue growth is steady, projected at $17.0B for 2026, while profitability metrics like a 23.01% ROE and 8.1% net income margin reflect operational strength. The company continues to innovate, launching new predictive analytics tools for life sciences clients.

The outlook for IQV remains positive, supported by strong earnings performance and analyst optimism, though investors should note valuation multiples above sector averages and debt levels. Key risks include competitive pressures in clinical research services and macroeconomic sensitivity affecting client spending.

Vir Biotechnology Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

IQV

No sentiment data available yet.

VIR
51% Buy49% Sell
Avg holding period · 0 Days

About IQVIA Holdings Inc. Common Stock

IQVIA provides clinical research, healthcare data, technology, and consulting services to life sciences companies. Its work supports drug development and commercialization.

Read more on IQV →

About Vir Biotechnology Inc. Common Stock

Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.

Read more on VIR →